CALA News and Press, Calithera Biosciences Inc. From 08/11/20

Image source: The Motley Fool. Calithera Biosciences Inc   (NASDAQ: CALA) Q2 2020 Earnings Call Aug 10, 2020 , 5:00 p.m. ET Operator Continue reading

The following companies have filed for mixed shelf offerings: More news on: Calithera Biosciences, Inc., Adaptimmune Therapeutics plc, PTC Therapeutics, Inc., Healthcare stocks news, , Read more ...

Calithera Biosciences, Inc. (CALA) Q2 2020 Earnings Conference Call Aug 10, 2020, 05:00 PM ET Company Participants Jennifer McNealey - IR Susan Molineaux - Founder, President and CEO Keith Orford - Chief Medical Officer Stephanie Wong - SVP of Finance Conference Call Partici...

Calithera Biosciences (NASDAQ: CALA ) : Q2 GAAP EPS of -$0.29 beats by $0.05 . More news on: Calithera Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 10, 2020-- SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and develop...

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today anno...

SOUTH SAN FRANCISCO, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences announced today the appointment of Scott Garland to its board of directors. Garland is a 29-year veteran of the biopharmaceutical industry who most recently served as the president and chief executive offic...

Calithera Biosciences (NASDAQ: CALA ) has dosed the first patients in its Phase 1b clinical trial of the arginase inhibitor CB-280 in adult patients with cystic fibrosis (CF) and chronic airway infection. More news on: Calithera Biosciences, Inc., Healthcare stocks news, Read more .....

SOUTH SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it...

KEAPSAKE is a planned Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinic...